Crestwood Advisors Group’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.35M | Buy |
100,274
+188
| +0.2% | +$4.67K | 0.05% | 190 |
|
|
2026
Q1 | $2.1M | Sell |
100,086
-45
| -0% | -$1.01K | 0.04% | 222 |
|
|
2025
Q4 | $2.3M | Sell |
100,131
-513
| -0.5% | -$16.9K | 0.04% | 206 |
|
|
2025
Q3 | $3.03M | Sell |
100,644
-85
| -0.1% | -$2.55K | 0.05% | 172 |
|
|
2025
Q2 | $3.66M | Sell |
100,729
-1
| -0% | -$36 | 0.07% | 154 |
|
|
2025
Q1 | $3.65M | Sell |
100,730
-1,000
| -1% | -$41.6K | 0.07% | 149 |
|
|
2024
Q4 | $4.28M | Buy |
101,730
+1,450
| +1% | +$71.9K | 0.08% | 136 |
|
|
2024
Q3 | $5.57M | Hold |
100,280
| – | – | 0.11% | 121 |
|
|
2024
Q2 | $4.12M | Buy |
100,280
+22
| +0% | +$939 | 0.09% | 131 |
|
|
2024
Q1 | $4.68M | Hold |
100,258
| – | – | 0.1% | 122 |
|
|
2023
Q4 | $4.79M | Hold |
100,258
| – | – | 0.11% | 122 |
|
|
2023
Q3 | $3.57M | Buy |
100,258
+70,350
| +235% | +$2.79M | 0.09% | 127 |
|
|
2023
Q2 | $1.38M | Hold |
29,908
| – | – | 0.04% | 120 |
|
|
2023
Q1 | $1.2M | Hold |
29,908
| – | – | 0.04% | 134 |
|
|
2022
Q4 | $1.39M | Hold |
29,908
| – | – | 0.05% | 125 |
|
|
2022
Q3 | $1.24M | Hold |
29,908
| – | – | 0.04% | 130 |
|
|
2022
Q2 | $1.78M | Hold |
29,908
| – | – | 0.06% | 122 |
|
|
2022
Q1 | $2.17M | Hold |
29,908
| – | – | 0.06% | 117 |
|
|
2021
Q4 | $2.52M | Hold |
29,908
| – | – | 0.07% | 116 |
|
|
2021
Q3 | $2.7M | Hold |
29,908
| – | – | 0.08% | 114 |
|
|
2021
Q2 | $2.85M | Hold |
29,908
| – | – | 0.08% | 110 |
|
|
2021
Q1 | $3.4M | Sell |
29,908
-1,100
| -4% | -$150K | 0.11% | 104 |
|
|
2020
Q4 | $4.29M | Hold |
31,008
| – | – | 0.14% | 100 |
|
|
2020
Q3 | $2.55M | Sell |
31,008
-1,100
| -3% | -$91.2K | 0.1% | 98 |
|
|
2020
Q2 | $2.51M | Sell |
32,108
-1,000
| -3% | -$66.2K | 0.1% | 101 |
|
|
2020
Q1 | $1.47M | Buy |
33,108
+400
| +1% | +$20.8K | 0.07% | 109 |
|
|
2019
Q4 | $1.4M | Sell |
32,708
-250
| -0.8% | -$10.3K | 0.06% | 118 |
|
|
2019
Q3 | $1.41M | Buy |
32,958
+250
| +0.8% | +$13.6K | 0.06% | 114 |
|
|
2019
Q2 | $2.08M | Hold |
32,708
| – | – | 0.09% | 107 |
|
|
2019
Q1 | $2.27M | Hold |
32,708
| – | – | 0.16% | 62 |
|
|
2018
Q4 | $1.42M | Sell |
32,708
-500
| -2% | -$27.3K | 0.11% | 68 |
|
|
2018
Q3 | $2.54M | Hold |
33,208
| – | – | 0.18% | 63 |
|
|
2018
Q2 | $2.54M | Buy |
33,208
+11,500
| +53% | +$743K | 0.18% | 62 |
|
|
2018
Q1 | $1.11M | Buy |
21,708
+500
| +2% | +$25.2K | 0.09% | 74 |
|
|
2017
Q4 | $984K | Hold |
21,208
| – | – | 0.08% | 79 |
|
|
2017
Q3 | $1.13M | Hold |
21,208
| – | – | 0.1% | 72 |
|
|
2017
Q2 | $1.42M | Hold |
21,208
| – | – | 0.12% | 70 |
|
|
2017
Q1 | $1.29M | Buy |
+21,208
| New | +$1.62M | 0.11% | 68 |
|
Other funds holding RARE
RI
FCM
Crestwood Advisors Group's RARE Position: Q2 2026 in Review
Crestwood Advisors Group increased its Ultragenyx Pharmaceutical (RARE) stake by 0.19% in Q2 2026, buying an estimated $4.67K and bringing the position to 100,274 shares worth $3.35M. The position accounts for 0.05% of the portfolio, ranked #190.
Crestwood Advisors Group first reported a position in RARE in Q1 2017 and has held it in 38 quarters since. The position peaked at $5.57M in Q3 2024. 310 funds tracked by Wall St. Rank hold RARE as of Q2 2026.
- Crestwood Advisors Group held 100,274 shares of Ultragenyx Pharmaceutical worth $3.35M as of Q2 2026.
- Crestwood Advisors Group bought 188 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $4.67K.
- Ultragenyx Pharmaceutical made up 0.05% of Crestwood Advisors Group's portfolio in Q2 2026, its #190 holding.
- Crestwood Advisors Group first reported a position in Ultragenyx Pharmaceutical in Q1 2017 and has held it in 38 quarters since.
- Crestwood Advisors Group's Ultragenyx Pharmaceutical position peaked at $5.57M in Q3 2024.
- 310 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.
Based on Crestwood Advisors Group's 13F filing for Q2 2026, filed 3 Aug 2026.